| scholarly article | Q13442814 |
| P50 | author | Michael R. Hayden | Q6833706 |
| Ryan R Brinkman | Q53584815 | ||
| P2093 | author name string | D Craufurd | |
| M Bloch | |||
| E W Almqvist | |||
| P2860 | cites work | Suicide risk in Huntington's disease | Q22306512 |
| Mutations of two PMS homologues in hereditary nonpolyposis colon cancer | Q24318484 | ||
| A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 | Q28115843 | ||
| Identification of the breast cancer susceptibility gene BRCA2 | Q29616290 | ||
| Causes of death in patients with Huntington's disease and in unaffected first degree relatives | Q33594807 | ||
| Increased rate of suicide among patients with Huntington's disease | Q33620527 | ||
| Prediction of psychological functioning one year after the predictive test for Huntington's disease and impact of the test result on reproductive decision making | Q33677759 | ||
| Adverse psychological events occurring in the first year after predictive testing for Huntington's disease. The Canadian Collaborative Study Predictive Testing | Q33677909 | ||
| Risk reversals in predictive testing for Huntington disease. | Q35249649 | ||
| Psychological costs and benefits of predictive testing for Huntington's disease | Q39481562 | ||
| Presymptomatic diagnosis of delayed-onset disease with linked DNA markers. The experience in Huntington's disease | Q39524394 | ||
| Unemployment and suicidal behaviour: a review of the literature | Q40185999 | ||
| Diagnosis of Huntington disease: a model for the stages of psychological response based on experience of a predictive testing program | Q40728773 | ||
| Non-participation in predictive testing for Huntington's disease: individual decision-making, personality and avoidant behaviour in the family. | Q40871387 | ||
| Long-term impact of Huntington disease linkage testing | Q40890939 | ||
| Presymptomatic testing for Huntington's disease in Wales 1987-90 | Q41107311 | ||
| Predictive testing for Huntington disease in Canada: the experience of those receiving an increased risk | Q41123560 | ||
| The complex pathology of trinucleotide repeats | Q41477080 | ||
| Presymptomatic testing for Huntington disease in the United States. | Q43146809 | ||
| Protocol for genetic testing in Huntington disease: Three years of experience in Minnesota | Q43713509 | ||
| Predictive testing for Huntington disease: I. Description of a pilot project in British Columbia | Q43782764 | ||
| The psychological consequences of predictive testing for Huntington's disease. Canadian Collaborative Study of Predictive Testing | Q44363828 | ||
| Predictive testing for Huntington's disease: risk perception, reasons for testing and psychological profile of test applicants. | Q45288622 | ||
| Self-selection in predictive testing for Huntington's disease | Q45288684 | ||
| Predictive testing for Huntington disease: social characteristics and knowledge of applicants, attitudes to the test procedure and decisions made after testing | Q45288734 | ||
| Attitudes toward direct predictive testing for the Huntington disease gene. Relevance for other adult-onset disorders. The Canadian Collaborative Group on Predictive Testing for Huntington Disease | Q45290219 | ||
| Predictive testing for Huntington disease in Canada: adverse effects and unexpected results in those receiving a decreased risk | Q45292147 | ||
| One hundred requests for predictive testing for Huntington's disease. | Q45292175 | ||
| Attitudes Towards Predictive Testing in Huntington's Disease-A Deep Interview Study in Sweden | Q45293069 | ||
| Few psychological consequences of presymptomatic testing for Huntington disease | Q45293652 | ||
| Three-year follow-up after presymptomatic testing for Huntington's disease in tested individuals and partners | Q45293786 | ||
| Predictors of psychological adjustment to genetic testing for Huntington's disease | Q45293791 | ||
| Reactions to predictive testing in Huntington disease: case reports of coping with a new genetic status | Q45295478 | ||
| Predictive testing for Huntington's disease with use of a linked DNA marker | Q45296919 | ||
| Suicide and attempted suicide in Huntington disease: implications for preclinical testing of persons at risk | Q45297711 | ||
| Attitudes of persons at risk for Huntington disease toward predictive testing | Q45298113 | ||
| Attitudes toward presymptomatic testing in Huntington disease | Q45298118 | ||
| Psychiatric implications of presymptomatic testing for Huntington's disease | Q45298382 | ||
| Huntington's chorea in Northamptonshire | Q45301780 | ||
| At Risk for Huntington's Disease: Who Should Know What and When? | Q45303497 | ||
| Social perspectives in Huntington's chorea | Q45306188 | ||
| Stigmatization of carrier status: social implications of heterozygote genetic screening programs | Q66841985 | ||
| Inheritance of torsion dystonia in jews | Q70933209 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | suicide | Q10737 |
| Huntington's disease | Q190564 | ||
| hospitalization | Q3140971 | ||
| attempted suicide | Q3518184 | ||
| suicide risk | Q47319077 | ||
| P304 | page(s) | 1293-1304 | |
| P577 | publication date | 1999-05-01 | |
| P1433 | published in | American Journal of Human Genetics | Q4744249 |
| P1476 | title | A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease | |
| P478 | volume | 64 |
| Q45292194 | "It was the missing piece": adolescent experiences of predictive genetic testing for adult-onset conditions |
| Q40602807 | A hereditary disorder in the family and the family life cycle: Huntington disease as a paradigm. |
| Q37323166 | A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases |
| Q45290516 | Accounts of suicidality in the Huntington disease community |
| Q45297686 | An international survey of predictive genetic testing in children for adult onset conditions |
| Q30660685 | An overview of psychiatric symptoms in Huntington's disease |
| Q35105749 | Clinical and Research Advances in Huntington's Disease |
| Q37029649 | Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer's disease |
| Q50954326 | Comparison of genotypic and phenotypic strategies for population screening in hemochromatosis: assessment of anxiety, depression, and perception of health. |
| Q47659519 | Completed suicide in an autopsy-confirmed case of early onset Alzheimer's disease. |
| Q37445171 | Dementia and suicidal behavior: a review of the literature |
| Q80246032 | Depression and suicidal ideation after predictive testing for Huntington's disease: a two-year follow-up study |
| Q34135724 | Estimating and disclosing the risk of developing Alzheimer‘s disease: challenges, controversies and future directions |
| Q92897643 | Ethical Considerations in Neuropsychiatric Disorders |
| Q35428275 | Ethical considerations in presymptomatic testing for variant CJD. |
| Q40601561 | Ethical dilemmas in testing for late onset conditions: reactions to testing and perceived impact on other family members |
| Q33334959 | Ethical issues in DNA testing |
| Q38951129 | Ethical issues in the evaluation of adults with suspected genetic neuromuscular disorders. |
| Q37282279 | Ethics in prion disease |
| Q45298405 | Factors related to genetic testing in adults at risk for Huntington disease: the prospective Huntington at-risk observational study (PHAROS). |
| Q38833267 | Genetic counseling and testing for Huntington's disease: A historical review |
| Q37170455 | Genetic susceptibility testing for neurodegenerative diseases: ethical and practice issues |
| Q101476439 | Genetic testing in dementia - utility and clinical strategies |
| Q35599446 | Genetic testing in inherited ataxias |
| Q47348626 | Genetics and patients' rights: where are the limits? |
| Q74595917 | Genetics of dementia |
| Q45306474 | Homozygosity in Huntington's disease: new ethical dilemma caused by molecular diagnosis |
| Q45301776 | Huntington disease: DNA analysis in Brazilian population |
| Q30306484 | Huntington's Disease |
| Q28284355 | Huntington's disease |
| Q22305906 | Huntington's disease genetics |
| Q45294644 | Huntington's disease research and practice: reflections on the journey made and lessons learned. |
| Q92325895 | Huntington's disease: a forensic risk factor in women |
| Q90005056 | Improving follow up after predictive testing in Huntington's disease: evaluating a genetic counselling narrative group session |
| Q40435328 | Long-term monitoring of the mortality trend of Huntington's disease in Austria |
| Q34325599 | Long-term outcome of presymptomatic testing in Huntington disease |
| Q45293277 | Mid- and long-term anxiety levels associated with presymptomatic testing of Huntington's disease, Machado-Joseph disease, and familial amyloid polyneuropathy |
| Q35172443 | Mouse models for neurological disease |
| Q31139428 | Neural bases of dysphoria in early Huntington's disease |
| Q48863476 | Overcrowding induces anxiety and causes loss of serotonin 5HT-1a receptors in rats |
| Q35572165 | Paradox of a better test for Huntington's disease |
| Q45297425 | Partners of mutation-carriers for Huntington's disease: forgotten persons? |
| Q81158583 | Patients' knowledge of cystic fibrosis: genetic determinism and implications for treatment |
| Q38565569 | Predictive gene testing for Huntington disease and other neurodegenerative disorders. |
| Q39354046 | Predictive genetic testing for amyotrophic lateral sclerosis and frontotemporal dementia: genetic counselling considerations. |
| Q45301909 | Predictive testing for Huntington's disease: the calm after the storm |
| Q44042899 | Predictive testing: more than just another test |
| Q45289285 | Predictive, pre-natal and diagnostic genetic testing for Huntington's disease: the experience in Canada from 1987 to 2000. |
| Q33959897 | Prenatal whole genome sequencing: just because we can, should we? |
| Q44740899 | Presymptomatic testing for neurogenetic diseases in Brazil: assessing who seeks and who follows through with testing |
| Q57021664 | Presymptomatic testing of those at 25% risk of autosomal dominant neurodegenerative disease- testing team beware |
| Q45290171 | Providing predictive testing for Huntington disease via telehealth: results of a pilot study in British Columbia, Canada |
| Q40413772 | Psychodynamic theory and counseling in predictive testing for Huntington's disease |
| Q40562181 | Psychological consequences and predictors of adverse events in the first 5 years after predictive testing for Huntington's disease. |
| Q45288483 | Psychological distress in the 5-year period after predictive testing for Huntington's disease |
| Q48412678 | Psychological follow-up of presymptomatic genetic testing for spinocerebellar ataxia type 2 (SCA2) in Cuba. |
| Q35431159 | Psychological functioning before predictive testing for Huntington's disease: the role of the parental disease, risk perception, and subjective proximity of the disease |
| Q42143817 | Recent advances in the management of choreas |
| Q91393942 | Reverse pre-symptomatic testing for Huntington disease: double disclosure when 25% at-risk children reveal the genetic status to their parent |
| Q92235502 | Risk factors for suicidality in Huntington disease: An analysis of the 2CARE clinical trial |
| Q64119432 | Sleep Disorders in Huntington's Disease |
| Q57778792 | Subtle Psychosocial Sequelae of Genetic Test Results |
| Q90592767 | Suicidal Ideation Assessment in Individuals with Premanifest and Manifest Huntington Disease |
| Q38422458 | Suicidal behavior and assisted suicide in dementia |
| Q35268087 | Suicidal behavior in prodromal Huntington disease |
| Q90896248 | Suicidal ideation is common in autosomal dominant Alzheimer's disease at-risk persons |
| Q40629976 | Suicide in Neurologic Illness |
| Q35435335 | Ten years of presymptomatic testing for Huntington's disease: the experience of the UK Huntington's Disease Prediction Consortium |
| Q41981872 | The clinical utility of gene testing for Alzheimer's disease |
| Q34702144 | The impact and desirability of news of risk for schizophrenia |
| Q51075911 | The psychological complexity of predictive testing for late onset neurogenetic diseases and hereditary cancers: implications for multidisciplinary counselling and for genetic education. |
| Q45292992 | The psychological dimension of informed consent: dissonance processes in genetic testing |
| Q36462035 | The search for cerebral biomarkers of Huntington's disease: a review of genetic models of age at onset prediction |
| Q45290127 | Therapeutic approach in Huntington's disease |
| Q40602800 | To test or not to test: interest in genetic testing for Alzheimer's disease among middle-aged adults |
| Q45301039 | United Kingdom experience with presymptomatic testing of individuals at 25% risk for Huntington's disease |
| Q37861589 | What is the role of genetic testing in movement disorders practice? |
| Q40421040 | What should we want to know about our future? A Kantian view on predictive genetic testing |
| Q52601552 | What to Do with a Second Chance in Life? Long-Term Experiences of Non-carriers of Huntington's Disease. |
| Q38542539 | Who Is at Risk for Psychological Distress in Genetic Testing Programs for Hereditary Cancer Disorders? |
| Q36639335 | Why tell asymptomatic children of the risk of an adult-onset disease in the family but not test them for it? |
Search more.